"BioDrain's sales have been on an upward growth trajectory these past few months — we have seen sales rapidly increase during the last two quarters and are confident that the momentum will continue to pick-up and this will be reflected in our upcoming earnings reports," said
Kornberg continued, "As the Company itself continues to evolve and expand, both in the U.S. and internationally, I look forward to working closely with these four industry leaders to make sure we are always keeping our eye on the goal: contributing to the creation of a safer, more environmentally friendly and cost conscious healthcare industry."
Alan J. Wein— Dr. Wein is an expert in the field of urology who has been practicing for more than 45 years. He is currently a Professor and Chief of the Division of Urologyat the University of Pennsylvaniaand is Chief of Urology and Director of the Residency Program in Urology at Penn Medicine. He has written almost one thousand published pieces and has penned, edited, and co-edited more than 30 books on urology.
Herbert Lepor— Dr. Lepor has been in the medical field for more than 35 years and is currently the Chairman of the Department of Urologyat New York University's Langone Medical Centerwhere he is also a Professor of Urology and Pharmacology. Dr. Lepor's primary clinical and basic research interests are related to the prostate; currently, his clinical practice is devoted exclusively to surgical management of prostate cancer. Dr. Lepor has served on the editorial boards of four major urological journals and has authored more than 191 peer-reviewed articles, 50 book chapters, and 12 books. He is also the co-founder and editor of Reviews in Urology.
Carl Schwartz— Dr. Schwartz has more than 25 years of experience in the field of dentistry; he currently owns and manages his own dental groups in Burton, Mich.and Grand Blanc, Mich.He previously owned and served as the chief operations officer of Plastics Research Corporation, one of the largest structural foam plastics company in the world. He also served on the board of Delta Dental Corporationof Michigan, was a member of the Michigan Advisory Board for Liberty Mutual Insuranceand was a member of the Board of Trusteesof the Museum of Contemporary Artin Fla.
James A. Fitzgerald Jr. — Mr. Fitzgeraldhas more than 35 years in the healthcare and investment space. He is a currently a Senior Advisor for Clayton Associates, an investment firm that serves as a leading source of equity capital for early-stage companies in the Southeast, where he advises the firm itself as well as FCA Venture Partners, its portfolio companies and prospective investments. Fitzgerald is also a partner with Clayton Advisors, a consulting firm specializing in healthcare. He is the former President of HealthTrust Purchasing Groupwhere he oversaw the initial formation of HealthTrust in 1999, its financial and operational functions and managed the contracting for clinical supplies, pharmaceuticals and capital equipment, totaling approximately $20 billionannually.
BioDrain's flagship technology, the STREAMWAY System, has gained traction in 2013 as customer trials increase with a 100 percent conversion to sales. Currently, there are numerous trials of the STREAMWAY System running in hospitals and surgical centers throughout
BioDrain's STREAMWAY System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, inability to raise sufficient additional capital to operate our business; unexpected costs and operating deficits, and lower than expected sales and revenues, if any; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the
Public Relations Contact:
Investor Relations Contacts:
212-896-1233 / 212-896-1239
News Provided by Acquire Media